Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lowenstein

Showing results (421-430 of 436) with videos related to

Pageof 44
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2023
Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote RadioresistanceStephen V Carney, Kaushik Banerjee, Anzar Mujeeb, et al.
Biorxiv : the Preprint Server for Biology|November 26, 2025
Reprogramming the Immune Suppressive Tumor Microenvironment in Glioma Enhances the Efficacy of Immune-Mediated Gene TherapyBrandon L McClellan, Jorge A Peña Agudelo, Anzar A Mujeeb, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2024
Epigenetic Reprogramming of Autophagy Drives Mutant IDH1 Glioma Progression and Response to RadiationFelipe J Núñez, Kaushik Banerjee, Anzar A Mujeeb, et al.
The Journal of Clinical Investigation|September 20, 2022
H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma modelsSantiago Haase, Kaushik Banerjee, Anzar A Mujeeb, et al.
NPJ Precision Oncology|August 14, 2025
A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizonCameron Crowell, Ziwen Zhu, Yingxiang Li, et al.
Science Advances|September 29, 2021
G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapyMahmoud S Alghamri, Brandon L McClellan, Ruthvik P Avvari, et al.
The Lancet. Oncology|September 1, 2023
Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trialYoshie Umemura, Daniel Orringer, Larry Junck, et al.
Research Square|September 18, 2025
Autophagy Upregulation in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma Uncovers a Novel Therapeutic TargetFelipe J Núñez, Kaushik Banerjee, Anzar A Mujeeb, et al.
ACS Nano|May 26, 2022
Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma ImmunotherapyMahmoud S Alghamri, Kaushik Banerjee, Anzar A Mujeeb, et al.
Neuro-Oncology|May 23, 2022
Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline gliomaDana Messinger, Micah K Harris, Jessica R Cummings, et al.
Pageof 44

Showing results (421-430 of 436) with videos related to

Sort By:
Pageof 44
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2023
Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote RadioresistanceStephen V Carney, Kaushik Banerjee, Anzar Mujeeb, et al.
Biorxiv : the Preprint Server for Biology|November 26, 2025
Reprogramming the Immune Suppressive Tumor Microenvironment in Glioma Enhances the Efficacy of Immune-Mediated Gene TherapyBrandon L McClellan, Jorge A Peña Agudelo, Anzar A Mujeeb, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2024
Epigenetic Reprogramming of Autophagy Drives Mutant IDH1 Glioma Progression and Response to RadiationFelipe J Núñez, Kaushik Banerjee, Anzar A Mujeeb, et al.
The Journal of Clinical Investigation|September 20, 2022
H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma modelsSantiago Haase, Kaushik Banerjee, Anzar A Mujeeb, et al.
NPJ Precision Oncology|August 14, 2025
A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizonCameron Crowell, Ziwen Zhu, Yingxiang Li, et al.
Science Advances|September 29, 2021
G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapyMahmoud S Alghamri, Brandon L McClellan, Ruthvik P Avvari, et al.
The Lancet. Oncology|September 1, 2023
Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trialYoshie Umemura, Daniel Orringer, Larry Junck, et al.
Research Square|September 18, 2025
Autophagy Upregulation in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma Uncovers a Novel Therapeutic TargetFelipe J Núñez, Kaushik Banerjee, Anzar A Mujeeb, et al.
ACS Nano|May 26, 2022
Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma ImmunotherapyMahmoud S Alghamri, Kaushik Banerjee, Anzar A Mujeeb, et al.
Neuro-Oncology|May 23, 2022
Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline gliomaDana Messinger, Micah K Harris, Jessica R Cummings, et al.
Pageof 44